Discovery of Novel EGFR Inhibitor Targeting Wild-Type and Mutant Forms of EGFR: In Silico and In Vitro Study
Molecules · 28.03.2023 · 28 (7) · 3014
DOI: 10.3390/molecules28073014 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, online erschienen am 28.03.2023. Verfasst von Duangjai Todsaporn und 11 weiteren Autor:innen. Beteiligte Einrichtung: Center of Excellence in Biocatalyst and Sustainable Biotechnology, Department of Biochemistry, Faculty of Science, Chulalongkorn University, Bangkok …. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Southern Federal University, Fundamental Scientific Research of the State Academies of Sciences, Thailand Science research and Innovation Fund Chulalongkorn University.
Abstract (Originalsprache)
Targeting L858R/T790M and L858R/T790M/C797S mutant EGFR is a critical challenge in developing EGFR tyrosine kinase inhibitors to overcome drug resistance in non-small cell lung cancer (NSCLC). The discovery of next-generation EGFR tyrosine kinase inhibitors (TKIs) is therefore necessary. To this end, a series of furopyridine derivatives were evaluated for their EGFR-based inhibition and antiproliferative activities using computational and biological approaches. We found that several compounds derived from virtual screening based on a molecular docking and solvated interaction energy (SIE) method showed the potential to suppress wild-type and mutant EGFR. The most promising PD13 displayed strong inhibitory activity against wild-type (IC50 of 11.64 ± 1.30 nM), L858R/T790M (IC50 of 10.51 ± 0.71 nM), which are more significant than known drugs. In addition, PD13 revealed a potent cytotoxic effect on A549 and H1975 cell lines with IC50 values of 18.09 ± 1.57 and 33.87 ± 0.86 µM, respectively. The 500-ns MD simulations indicated that PD13 formed a hydrogen bond with Met793 at the hinge region, thus creating excellent EGFR inhibitory activity. Moreover, the binding of PD13 in the hinge region of EGFR was the major determining factor in stabilizing the interactions via hydrogen bonds and van der Waals (vdW). Altogether, PD13 is a promising novel EGFR inhibitor that could be further clinically developed as fourth-generation EGFR-TKIs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center of Excellence in Biocatalyst and Sustainable Biotechnology, Department of Biochemistry, Faculty of Science, Chulalongkorn University, Bangkok 10330, Thailand.
- North-Caucasian Zonal Research Veterinary Institute, 346406 Novocherkassk, Russia.
- InterBioScreen Ltd., 85355 Moscow, Russia.
- Department of Biochemistry, Faculty of Science, Kasetsart University, Bangkok 10900, Thailand.
- Department of Biochemistry, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand.
- Department of Pharmaceutical Chemistry, School of Pharmacy, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
ORCID-Profile: Thitinan Aiebchun, Panupong Mahalapbutr, Anthi Petrou, Athina Geronikaki, Liudmila Divaeva, Ilkay Yildiz, Kiattawee Choowongkomon
Förderung
- Southern Federal University
- Fundamental Scientific Research of the State Academies of Sciences
- Thailand Science research and Innovation Fund Chulalongkorn University
- Thailand Science Research and Innovation Fund, Chulalongkorn University
Zitieren
APA
Todsaporn, D., Zubenko, A., Kartsev, V., Aiebchun, T., Mahalapbutr, P., Petrou, A., Geronikaki, A., Divaeva, L., Chekrisheva, V., Yildiz, I., Choowongkomon, K., & Rungrotmongkol, T. (2023). Discovery of Novel EGFR Inhibitor Targeting Wild-Type and Mutant Forms of EGFR: In Silico and In Vitro Study. Molecules, 28(7), 3014. https://doi.org/10.3390/molecules28073014
Vancouver
Todsaporn D, Zubenko A, Kartsev V, Aiebchun T, Mahalapbutr P, Petrou A, et al. Discovery of Novel EGFR Inhibitor Targeting Wild-Type and Mutant Forms of EGFR: In Silico and In Vitro Study. Molecules. 2023;28(7):3014. doi:10.3390/molecules28073014
BibTeX
@article{Todsaporn2023,
author = {Todsaporn, Duangjai and Zubenko, Alexander and Kartsev, Victor and Aiebchun, Thitinan and Mahalapbutr, Panupong and Petrou, Anthi and Geronikaki, Athina and Divaeva, Liudmila and Chekrisheva, Victoria and Yildiz, Ilkay and Choowongkomon, Kiattawee and Rungrotmongkol, Thanyada},
title = {Discovery of Novel EGFR Inhibitor Targeting Wild-Type and Mutant Forms of EGFR: In Silico and In Vitro Study},
journal = {Molecules},
year = {2023},
volume = {28},
number = {7},
pages = {3014},
doi = {10.3390/molecules28073014}
}
EUVIMED